Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Alzheon, Inc. is navigating 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are being handled by 3 distinct examiners. The portfolio's current activity spans 2 distinct art units, suggesting that the 3 pending actions involve different technical focuses within the biotech sector. This distribution across 2 distinct art units and 3 distinct examiners requires the applicant to be prepared for different examination styles and art unit-specific requirements, which can impact the overall prosecution timeline.
WILLIS, DOUGLAS M is identified as the busiest examiner with 1 pending office action. Since there are 3 distinct examiners for the 3 total pending office actions, each examiner is currently reviewing a single application. This spread across 2 distinct art units means that no single examiner has a majority share of the workload. The busiest examiner pending count of 1 indicates that the company's 3 pending office actions are being prosecuted independently by different individuals at the office, necessitating a coordinated effort to ensure consistency across the 2 distinct art units involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| MARTINEZ, TARA L | 1 | 62.6% | +65.4% |
| GOLDBERG, JEANINE ANNE | 1 | 45.8% | +40.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717139 | ALZ-801 FOR USE IN TREATING ALZHEIMER'S DISEASE | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17877380 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | MARTINEZ, TARA L | 105d overdue |
| 17619398 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GOLDBERG, JEANINE ANNE | 6d |
| 18717139 | ALZ-801 FOR USE IN TREATING ALZHEIMER'S DISEASE | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717139 | ALZ-801 FOR USE IN TREATING ALZHEIMER'S DISEASE | WILLIS, DOUGLAS M | — | §102§112DP | Non-Final OA | — | Pending | Jun 06, 2024 |
| 17877380 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | MARTINEZ, TARA L | 1654 | §103DP | Final Rejection | 105d overdue | Pending | Jul 29, 2022 |
| 17619398 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GOLDBERG, JEANINE ANNE | 1682 | Other | Final Rejection | 6d | Pending | Dec 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial